Literature DB >> 33665631

Analysis of T cells in mouse lymphoid tissue and blood with flow cytometry.

Ioannis Skordos1,2, Annelies Demeyer1,2, Rudi Beyaert1,2.   

Abstract

T cells play a key role in adaptive immunity. Defects in specific T cell receptors or signaling proteins can alter their frequency and activation status, which may be associated with immune disease or cancer. Monitoring of T cell frequency and function in genetically modified mice or murine models of disease is therefore of high interest. Here, we provide a detailed protocol to analyze regulatory T cells, T cell activation, and cytokine production in thymus, spleen, or blood via flow cytometry. For complete details on the use and execution of this protocol, please refer to Demeyer et al. (2020).
© 2021 The Author(s).

Entities:  

Keywords:  Flow cytometry/mass cytometry; Immunology

Mesh:

Year:  2021        PMID: 33665631      PMCID: PMC7907922          DOI: 10.1016/j.xpro.2021.100351

Source DB:  PubMed          Journal:  STAR Protoc        ISSN: 2666-1667


Before you begin

Mice

Before starting with this protocol, ensure that you have sufficient amounts of age- and sex-matched control and genetically modified mice from the appropriate mouse strain. We recommend using mice older than 8-weeks for T cell studies (Jackson et al., 2017). To guarantee a pronounced statistical significance, we suggest using a minimum amount of 5 animals per group.

Prepare flow cytometric panels

Timing: 0.5–1 h Set up the flow panels to study T cells in thymus, spleen, and blood of mice and ensure that you have sufficient amounts of flow cytometry antibodies for the number of samples you want to analyze.

Prepare reagents

Timing: 1–4 h, can be done the days prior to the day of the protocol Make sure you have all reagents mentioned under Materials and equipment.

Prepare materials for blood and lymphoid tissue collection / processing

Timing: 0.5–1 h, can be done the day prior to the day of the protocol Assure that you have all the necessary materials for blood and lymphoid tissue collection/processing. Prepare blood collection tubes by adding 50 μL EDTA (500 mM) in 1.5 mL Eppendorfs. Prepare collection tubes for the spleen by adding 3 mL T cell culture medium in 15 mL tubes. Prepare collection tubes for the thymus by adding 1 mL T cell culture medium in 1.5 mL Eppendorfs. Prepare 15 mL tubes containing 5 mL of ACK lysis buffer for blood samples. Pre-label all the required 15 and 50 mL tubes needed to make single-cell suspensions.

Key resources table

Materials and equipment

T cell culture medium

To make 500 mL of T cell culture medium, dissolve 5 mL 200 mM L-glutamine (final concentration 2 mM), 5 mL Penicillin-streptomycin, 1 mL 50 mM 2-mercaptoethanol (final concentration 0.1 mM), 1 mL 100 mM sodium pyruvate solution (final concentration 0.2 mM) and 50 mL of heat inactivated Fetal Bovine Serum (final concentration 10%) in 438 mL of RPMI 1640 and filter the culture media using a GP sterile vacuum filtration system. Store at 4°C for up to 1 month.

Fixable viability dye

Prepare a working solution of the Fixable Viability Dye eFluor 506 by adding 450 μL of 1× D-PBS to the vial (final concentration 1:10). Store at −80°C in 50 μL aliquots for up to 6 months.

Azide

To make 10 mL of Azide, dissolve 2 g Azide in 10 mL of ultra-pure water (final concentration 20% w/v). Store at 4°C for up to 1 year.

EDTA (500 mM)

To make 500 mM EDTA, dissolve 186.12 g EDTA disodium dihydrate in 1,000 mL ultra-pure water and adjust the buffer's pH to 8 by adding 5 M NaOH. Store at 4°C for up to 6 months.

FACS buffer

To prepare 1 L of FACS buffer, dissolve 1 g BSA (final concentration 0.1%), 4 mL 500 mM EDTA (final concentration 2 mM) and 1 mL 20% Azide (final concentration 0.02%) in 900 mL 1× D-PBS and adjust the volume to 1,000 mL with 1× D-PBS. Store at 4°C for up to 6 months.

Fc blocking buffer

To make Fc blocking buffer for 1 sample, add 1 μL of anti-CD16/32 antibody (Key resources table) into 99 μL 1× D-PBS. ALWAYS prepare freshly. Store at 4°C for up to 24 h.

PMA

Prepare a PMA stock solution by dissolving 5 mg PMA in 5 mL DMSO (final concentration 1 mg/mL) under aseptic conditions. Store at −20°C in 50 μL aliquots for up to 1 year.

Ionomycin

Prepare an ionomycin stock solution by dissolving 1 mg ionomycin in 1.338 mL 1× D-PBS (final concentration 747 μg/mL) under aseptic conditions. Store at 4°C in 20 μL aliquots for up to 1 year.

Brefeldin A (BFA)

Prepare a BFA stock solution by adding 250 μL of DMSO to the vial (final concentration 20 μg/μL) under aseptic conditions. Store at −20°C in 15 μL aliquots for up to 1 year.

70% Ethanol

To make 500 mL 70% ethanol, mix 350 mL of absolute ethanol with 150 mL of tap water. Store at 20°C–25°C.

0.1% Trypan blue

Prepare a 0.1% trypan blue stock solution by dissolving 50 mg trypan blue powder in 50 mL 1× D-PBS under aseptic conditions. Store at 20°C–25°C in 1.5 mL aliquots.

Step-by-step method details

Sampling

Timing: 10 min/mouse This step contains information on collecting blood, thymus, and spleen from mice to study T cells. Euthanize the mouse by CO2 inhalation. Place the animal on its back on a dissection mat, pin the paws on the mat and wet the fur by spraying with 70% ethanol. Make an incision in the abdominal area above the urethral opening, without penetrating the abdominal wall, and extend the incision until the neck with a pair of straight scissors. Extent also the incision to the hind legs and pin the loose skin on the mat. To study circulating T cells, collect blood by cardiac puncture. Penetrate the diaphragm from the xiphoid with a pair of straight scissors and delicately cut the ribs on each side up to the clavicle. Then lift the ribs with a pair of straight forceps with blunt points, pin them to the mat and insert a 26G × 1/2 inch needle attached to a 1 mL syringe in the lower left ventricle part of the heart to collect up to 500 μL of blood. Finally, transfer the blood to a 1.5 mL blood collection tube containing 50 μL EDTA (500 mM), invert the tube 5 times, to avoid blood clotting, and store the sample on ice. For long-term in vivo monitoring of lymphocytes in mice, one can obtain circulating lymphocytes via submandibular vein puncture instead of cardiac puncture. Next, isolate the thymus by disconnecting the connective tissue surrounding the thymus and gently remove the thymic lobes using a pair of curved forceps. Place the thymus into a 1.5 mL collection tube containing 1 mL of T cell culture medium and store it on ice. CRITICAL: While cutting the ribs and during the cardiac puncture avoid cutting the thoracic blood vessels, since this will lead to blood leakage and contamination of the thoracic cavity with circulating lymphocytes. If there is blood leakage, the thymus needs to be rinsed in 1× D-PBS before placing the thymus in the collection tube. Finally, isolate the spleen by making a 1.5 cm incision in the peritoneum and gently pull the spleen to the surface. Clean up the spleen by removing the pancreatic tissue attached to the spleen with a pair of straight scissors and transfer the spleen with a pair of straight, blunt pointed forceps to a 15 mL collection tube containing 3 mL of T cell culture medium.

Processing of samples

Timing: 1.5–2 h This step details how to prepare single-cell suspensions from spleen, thymus, and blood. Online one can find more info concerning this procedure: https://www.youtube.com/watch?v=N0jftyYqM38 and https://www.jove.com/v/61008/flow-cytometry-analysis-immune-cell-subsets-within-murine-spleen-bone. Spleen Pour the spleen with T cell culture medium into a 10 mm bacterial Petri dish. CRITICAL: For maintaining aseptic conditions, work under a fume hood. While holding the spleen in the Petri dish with a pair of straight forceps with blunt points, flush out the splenocytes by injecting T cell culture medium (collected from the Petri dish) in the spleen with a 3 mL syringe (26G × 1/2 inch needle). Smash the spleen by using the plunger of the 3 mL syringe and a pair of straight blunt pointed forceps. Transfer the medium containing the smashed spleen to a 70 μm cell strainer on top of a 50 mL tube. Use the plunger again to smash the remaining spleen pieces on the cell strainer. Rinse the Petri dish with 3 mL of T cell culture medium to get all remaining spleen pieces and transfer them to the 70 μm cell strainer. Smash the remaining spleen pieces. Rinse the 70 μm cell strainer with 3 mL of T cell culture medium, discard the cell strainer, and place the sample immediately on ice. Centrifuge the sample at 400 × g for 4 min at 4°C. To decrease experimental time if you are working alone, we advise to start preparing thymic single-cell suspensions during the centrifugation steps of splenocytes isolation. Discard supernatant using a vacuum pump and add 2 mL of ACK lysis buffer to the 50 mL tube, close the tube, and resuspend the splenocytes by pulse vortexing. Incubate for 3 min at 20°C–25°C. Add 6 mL of T cell culture medium to stop the lysis of red blood cells, place the 50 mL tube on ice and centrifuge the sample at 400 × g for 4 min at 4°C. Discard the supernatant and resuspend the splenocytes with 3 mL of T cell culture medium and keep on ice until stimulation/staining. Count splenocytes with a counting chamber (1:100 dilution in 0.1% trypan blue). Thymus Transfer the thymus to a 70 μm cell strainer on top of a 50 mL tube using a clean pair of straight forceps with blunt points. Smash the thymus on the cell strainer using the plunger of a new 3 mL syringe and rinse the cell strainer with 3 mL of T cell culture medium. Smash the remaining thymus pieces, rinse the cell strainer once more with 3 mL of T cell culture medium and place the sample on ice. Centrifuge the sample at 400 × g for 4 min at 4°C. Discard the supernatant and resuspend the thymocytes with 3 mL of T cell culture medium and keep on ice until staining. Count thymocytes with a counting chamber (1:100 dilution in 0.1% trypan blue). Blood Transfer the blood sample to a 15 mL tube containing 5 mL of ACK lysis buffer, close tube, vortex shortly (5 s) and incubate at RT for 3 min. Put the tubes back on ice and add 8 mL cold T cell culture medium to stop red blood cells lysis. Centrifuge the sample at 400 × g for 4 min at 4°C. Discard the supernatant and resuspend the cells with 200 μL of T cell culture medium. Keep on ice until staining. Most of the time, this experiment is labor-intensive. Therefore, we recommend having ≥ two people working together to prepare single-cell suspensions (preferably one researcher per tissue). Instead of T cell culture medium, one can use 1× D-PBS for the rinsing steps and to stop the ACK lysis step.

Stimulation of splenocytes for intracellular cytokine staining (ICS)

Timing: 4.5 h This step details how to stimulate splenic single-cell suspensions with PMA/ionomycin/BFA to assess the intracellular cytokine production of T cells. Stimulation of splenocytes Prepare a 10× mix of PMA/ionomycin/BFA by adding 0.5 μL PMA, 6.66 μL ionomycin and 5 μL BFA to 987.84 μL T cell culture medium (concentration 500 ng/mL, 5,000 ng/mL and 100 μg/mL, respectively). The volume needed is 20 μL/sample. Prepare a 10× mix with only BFA by adding 0.5 μL BFA to 99.5 μL T cell culture medium (concentration 10 μg/mL). The volume needed is 20 μL/sample. After use, immediately place the stock solution of ionomycin at 4°C and the stock solutions of PMA and BFA at −20°C. Transfer 1.5 million splenocytes to a well of a 48-well flat-bottom culture plate. Adjust the volume in the well at 180 μL by adding T cell culture medium. The flow cytometry analysis requires additional samples for unstained, single-stained cell, and negative cell controls, as described in step 10c. You need one negative cell control, one unstained control and ten single-stained cell control samples (see Tables 7 and 8).
Table 7

Antibody mix for the extracellular staining of PMA/ionomycin-stimulated splenic T cells

FluorophoreMarkerFinal dilutionVolume for 1 sample
eFluor 506Fixable Viability Dye1/2000.5 μL
CD16/32 (Mouse BD Fc Block)1/1001 μL
PE-Cy5CD3e1/2000.5 μL
BUV395CD41/2000.5 μL
FITCCD8a1/2000.5 μL
PECD441/2000.5 μL
BUV496CD45R/B2201/4000.25 μL
Sum of antibodies3.75 μL
1× D-PBS46.25 μL
BD Horizon Brilliant Stain Buffer1/250 μL
Final staining volume100 μL
Table 8

Antibody mix for the intracellular staining of PMA/ionomycin-stimulated splenic T cells

FluorophoreMarkerFinal dilutionVolume for 1 sample
PE-Cy7IFN-γ1/1600.63 μL
APC-Cy7IL-21/2000.5 μL
APCIL-41/1001 μL
PerCP-Cyanine5.5IL-171/1600.63 μL
Alexa Fluor 700TNF1/1001 μL
Sum of antibodies3.76 μL
1× Permeabilization Buffer from BD Cytofix/Cytoperm kit96.24 μL
Final staining volume100 μL
Add 20 μL of the PMA/ionomycin/BFA mix (final concentration for T cell stimulation is 50 ng/mL, 500 ng/mL, 10 μg/mL, respectively) to all samples, with the exception of the negative control sample to which 20 μL of the BFA only mix (final concentration 10 μg/mL) is added. Place the culture plate in a 37°C, 5% CO2 cell culture incubator for 4 h. After 4 h, place the culture plate on ice until intracellular cytokine staining. CRITICAL: For maintaining aseptic conditions, work under a fume hood.

Flow cytometry antibody staining of T cells in blood, thymus, and spleen

Timing: 5–6 h This step details the staining of splenic, thymic and blood single-cell suspensions with fluorophore-conjugated anti-mouse antibodies (see Tables 1, 2, 3, 4, 5, 6, 7, and 8) to study T cells in spleen, thymus, and blood. Single-stained cell control samples are needed to set the PMT voltage for each parameter and single-stained eBeads (UltraComp eBeads Compensation beads) controls are needed for compensation, except for the Fixable Viability Dye for which cells will be used. Figure 1 shows an example of a plate layout to stain for T cell activation and Treg cell functionality in ten mouse spleens.
Table 1

Antibody mix for the extracellular staining of splenic T cells

FluorophoreMarkerFinal dilutionVolume for 1 sample
eFluor 506Fixable viability dye1/2000.5 μL
CD16/32 (mouse BD Fc block)1/1001 μL
PE-Cy5CD3e1/2000.5 μL
APC-eFluor 780CD41/2000.5 μL
PE-Cy7CD8a1/6000.16 μL
BUV395CD251/1001 μL
Alexa Fluor 700CD441/1001 μL
PECD62L1/2000.5 μL
BV421CD120b1/1001 μL
Sum of antibodies6.16 μL
1× D-PBS43.84 μL
BD Horizon Brilliant Stain Buffer1/250 μL
Final staining volume100 μL
Table 2

Antibody mix for the intracellular staining of splenic T cells

FluorophoreMarkerFinal dilutionVolume for 1 sample
PE-eFluor 610CD1521/502 μL
APCFoxP31/502 μL
Sum of antibodies4 μL
1× Permeabilization Buffer from FoxP3/Transcription Factor Staining Buffer Set96 μL
Final staining volume100 μL
Table 3

Antibody mix for the extracellular staining of thymic T cells

FluorophoreMarkerFinal dilutionVolume for 1 sample
eFluor 506Fixable Viability Dye1/2000.5 μL
CD16/32 (Mouse BD Fc Block)1/1001 μL
APC-eFluor 780CD41/2000.5 μL
PE-Cy7CD8a1/6000.16 μL
Sum of antibodies2.16 μL
1× D-PBS97.84 μL
Final staining volume100 μL
Table 4

Antibody mix for the intracellular staining of thymic T cells

FluorophoreMarkerFinal dilutionVolume for 1 sample
APCFoxP31/502 μL
Sum of antibodies2 μL
1× Permeabilization Buffer from FoxP3/Transcription Factor Staining Buffer Set98 μL
Final staining volume100 μL
Table 5

Antibody mix for the extracellular staining of T cells in the blood of mice

FluorophoreMarkerFinal dilutionVolume for 1 sample
eFluor 506Fixable Viability Dye1/2000.5 μL
CD16/32 (Mouse BD Fc Block)1/1001 μL
PE-Cy5CD3e1/2000.5 μL
APC-eFluor 780CD41/2000.5 μL
PE-Cy7CD8a1/2000.5 μL
Alexa Fluor 700CD441/2000.5 μL
eFluor 450CD62L1/2000.5 μL
Sum of antibodies4 μL
1× D-PBS96 μL
Final staining volume100 μL
Table 6

Antibody mix for the intracellular staining of T cells in the blood of mice

FluorophoreMarkerFinal dilutionVolume for 1 sample
APCFoxP31/502 μL
Sum of antibodies2 μL
1× Permeabilization Buffer from FoxP3/Transcription Factor Staining Buffer Set98 μL
Final staining volume100 μL
Figure 1

Layout of a 96-well v-bottom plate setup for the staining of splenic T cell activation and Treg cell functionality of ten mice

Splenocytes are stained with the antibody mix for the extracellular staining and the intracellular staining as indicated in Tables 1 and 2 and described in step 12, single-stained cell controls and eBeads compensation controls are stained with the indicated fluorophore-conjugated anti-mouse antibodies, based on Tables 1 and 2. FMO, fluorescence minus one; FVD, fixable viability dye.

CRITICAL: All antibodies and buffers should be kept on ice while preparing antibody mixes. Tables 1, 2, 3, 4, 5, 6, 7, and 8 provide antibody volumes to stain one sample (final staining volume 100 μL). To stain more than one sample, prepare an excess of two samples by multiplying the indicated volumes by the number of samples + 2. To aid with the discrimination of certain gates, one can set up fluorescent minus one (FMO) controls, where the marker of interest is omitted from the staining mix. In this protocol we recommend the use of FMO controls for CD152 (CTLA4) and the CD120b (TNFR2) antibodies to aid the gating for CTLA4+ and TNFR2+ Treg cells. However, the use of FMO controls can be extended to other markers, depending on the experience of the researcher. Before you begin with the antibody staining, freshly prepare the following: eBeads mix: add 7 drops from the stock vial to a 15 mL tube containing 7 mL 1× D-PBS (1 drop/mL). Vortex thoroughly and keep on ice. 200 μL of eBeads mix is required per anti-mouse antibody. Antibody mixes for the extracellular staining of cells with fluorophore-conjugated anti-mouse antibodies in the appropriately labeled 1.5 mL Eppendorfs, by following the volumes indicated in Tables 1, 3, 5, and 7. Start by adding 1× D-PBS to a 1.5 mL Eppendorf. The volume of 1× D-PBS for one sample is based on the following formula: volume of 1× D-PBS = 100 μL (final staining volume/sample) - sum of antibodies - volume of BD Horizon Brilliant Stain Buffer. Continue by adding BD Horizon Brilliant Stain Buffer (at a dilution of 1/2 of the final staining volume). CRITICAL: BD Horizon Brilliant Stain Buffer is required when more than one BD Horizon Brilliant dye-conjugated antibody is used in the same flow panel to prevent the non-specific polymer interactions which can lead to data appearing under-compensated. In this experiment, BD Horizon Brilliant Stain Buffer is used only in the antibody mixes of Tables 1 and 7. Continue by adding fluorophore-conjugated anti-mouse antibodies and the Fixable Viability Dye. Once finished, vortex for 5 s. Store mixes in the fridge at 4°C. The antibody mixes can be made the day before, but the Fixable Viability Dye has to be added just before adding the staining mix to the samples. We use Fixable Viability Dye eFluor 506 because its emission spectrum is compatible with our antibody staining panels. Alternatives, with similar emission properties, are the Zombie Aqua Fixable Viability Kit from BioLegend (cat# 23101) and the LIVE/DEAD Fixable Aqua Dead Cell Stain Kit by Invitrogen (cat# L34957). For the panel described in Tables 1 and 2, the LIVE/DEAD Fixable Green Dead Cell Stain Kit by Invitrogen (cat# L23101), with different emission properties, can be used instead of Fixable Viability Dye eFluor 506. These alternative viability dyes have not been tested and need further optimization. CRITICAL: Since this experiment is labor-intensive, we recommend starting with the staining of T cells in splenic, thymic and blood single-cell suspensions during the 4 h incubation period of PMA/ionomycin/BFA-stimulated splenocytes. CRITICAL: Since some surface markers like CD62L are temperature sensitive, always keep the 96-well v-bottom polypropylene plate on ice during the staining procedure and use a centrifuge set at 4°C. CRITICAL: All incubation steps should be done in the dark. Staining for T cell activation and Treg cell functionality in the spleen of mice (see Figure 1 for a layout of a 96-well plate to stain splenocytes from ten mice). Transfer 1.5 million splenocytes into a well of a 96-well polypropylene v-bottom plate. Keep the plate on ice. Add an unstained cell control and 10 single-stained cell controls by transferring 1.5 million splenocytes into 11 wells of the 96-well v-bottom plate. For the CD152 FMO and the CD120b FMO you need two additional wells with 1.5 million cells. Heat-kill 1.5 million splenocytes for 1 min at 95°C to generate a positive cell control for dead cells. Place heat-killed cells on ice for 1 min. Mix heat-killed cells with 1.5 million splenocytes of a single-stained cell control sample. Use this sample as a single-stained cell control for the Fixable Viability Dye. Centrifuge the plate at 400 × g for 4 min at 4°C. Discard the supernatant and resuspend cell pellets with 200 μL 1× D-PBS. Centrifuge the plate at 400 × g for 4 min at 4°C. Discard the supernatant and resuspend cell pellets with 100 μL of extracellular staining antibody mix (see Table 1). Resuspend the CD152 FMO control in 100 μL of antibody mix for the extracellular staining. Be aware, do not add anti-CD120b antibody in the extracellular staining antibody mix for the CD120b FMO. Resuspend unstained and single-stained cell controls with 100 μL of Fc blocking buffer (see Materials and equipment) and add x μL of the relevant extracellular staining antibody to the proper sample. Do not add antibody to the single-stained cell controls used for the detection of intracellular FoxP3 and CD152. In this case x μL is calculated based on the antibody's final dilution, as indicated in Table 1. Add 200 μL of eBeads mix to ten wells of the 96-well v-bottom plate and add 0.5 μL of the corresponding extracellular antibody, except for Alexa Fluor 700 and for APC-eFluor780: 1 μL and for PE, PE-tandem, and BV dyes: 0.2 μL. In this protocol, we use eBeads as compensation controls. We are aware that some labs prefer single-stained cell for compensation controls in multicolor flow cytometry experiments. However, for proper compensation one needs a distinct negative and positive population. This will be challenging for markers expressed on a low number of cells, such as FoxP3 and some intracellular cytokines. Therefore, we use eBeads that have a robust signal regardless of the fluorophore-conjugated antibody that is bound. These eBeads consist of two populations of beads: one that captures any mouse, rat, or hamster antibody and one that does not react with antibodies. Adding a fluorophore-conjugated antibody will result in a negative and positive peak, generating a bimodal distribution that can be used to perform compensation. Most of the fluorophore-conjugated antibodies produce an optimal bimodal distribution at average concentrations. However, we have determined that for very bright fluorophores, such as PE, PE-tandem, and BV dyes, less antibody should be used to keep the positive peak on scale. In contrast, we have observed that for dim fluorophores, such as AF700, APC-Cy7, and APC-eFluor780, more antibody is needed to achieve an optimal separation of the two peaks. CRITICAL: Since eBeads precipitate rapidly, vortex eBeads mix thoroughly while adding them to the 96-well v-bottom plate. Mix samples and eBeads by pipetting up and down and incubate on ice for 20 min in the dark. During the incubation of samples with the antibody mix for extracellular staining, prepare all required buffers to detect intracellular FoxP3 and CTLA4 expression in T cells, as described in the datasheet of the eBioscience Foxp3/Transcription Factor Staining Buffer Set (https://www.thermofisher.com/document-connect/document-connect.html?url=https%3A%2F%2Fassets.thermofisher.com%2FTFS-Assets%2FLSG%2Fmanuals%2F00-5523.pdf&title=VGVjaG5pY2FsIERhdGEgU2hlZXQ6IEZveHAzIC8gVHJhbnNjcmlwdGlvbiBGYWN0b3IgU3RhaW5pbmcgQnVmZmVyIFNldA). Add 100 μL 1× D-PBS to each sample, beads excluded, and centrifuge at 400 × g for 4 min at 4°C. Discard the supernatant and resuspend samples and eBeads with 100 μL fixation buffer. Incubate samples on ice for 30 min in the dark. Prepare the antibody mix for the intracellular staining (see Table 2) in an appropriately labeled 1.5 mL Eppendorf and store in the fridge at 4°C. Start by adding 1× Permeabilization buffer. Continue by adding fluorophore-conjugated anti-mouse antibodies. Centrifuge plate at 400 × g for 4 min at 4°C. Discard the supernatant and resuspend cell pellets with 100 μL of intracellular staining antibody mix. Resuspend the CD120b FMO control in 100 μL of antibody mix for intracellular staining. Be aware, do not add anti-CD152 antibody in the intracellular staining antibody mix for the CD152 FMO. Resuspend unstained and single-stained cell controls with 100 μL 1× Permeabilization buffer and add x μL of the relevant intracellular staining antibody to the proper sample. In this case x μL is calculated based on the antibody's final dilution, as indicated in Table 2. Resuspend eBeads with 200 μL 1× Permeabilization buffer and add 0.5 μL of the corresponding intracellular antibody to the beads, except for PE-tandem dyes: 0.2 μL. Incubate samples on ice for 30 min in the dark. Add 100 μL 1× Permeabilization buffer to each sample (not to the eBeads) and centrifuge at 400 × g for 4 min at 4°C. Discard the supernatant and resuspend cell pellets and eBeads with 200 μL FACS buffer (see Materials and equipment). Transfer samples to pre-labeled 1.2 mL FACS tubes and store samples in the fridge at 4°C until detection. Pause point: Since the cells are fixed, one can collect the data the following day. Staining of T cells and Treg cells in thymic and blood single-cell suspensions Transfer 1–1.5 million thymocytes and 100 μL of the blood single-cell suspension containing ∼ 0.2–1 million white blood cells into two distinct 96-well polypropylene v-bottom plates (pre-labeled as thymus and blood plate). Keep both plates on ice. Set up an unstained cell control and four single-stained cell controls by transferring 1.5 million thymocytes to the thymus-labeled 96-well v-bottom plate. Set up an unstained cell control and seven single-stained cell controls by transferring 50 μL of the blood single-cell suspension (a pool of the blood samples can be used) to the blood-labeled 96-well v-bottom plate. Set up single-stained cell controls for the Fixable Viability Dye (1:1 mix of alive and heat-killed cells) in both plates as described in steps 12c and d. Continue with the extracellular and intracellular antibody staining of thymocytes and white blood cells by following the previously described steps 12e–w. Always refer to Tables 3 and 6 for the appropriate antibody mix for intracellular staining. Pause point: Since the cells are fixed, one can collect the data the following day. Intracellular cytokine staining of PMA/ionomycin/BFA-stimulated splenic T cells Transfer all samples from the 48-well flat-bottom culture plate to a 96-well polypropylene v-bottom plate and keep the plate on ice. To detach all splenocytes from the bottom of the 48-well culture plate and increase cell yield, loosen the cells by pipetting up and down a couple of times (clockwise). Generate a single-stained cell control for the Fixable Viability Dye by heat-killing 100 μL of a single-stained cell control sample as described in steps 12c and d. Centrifuge the plate at 400 × g for 4 min at 4°C. Discard the supernatant, resuspend cell pellets with 200 μL 1× D-PBS and follow the same procedure of extracellular staining with antibodies as described in steps 12g–l. Always refer to Table 7 for the appropriate extracellular antibody mix for the staining of cells. During the incubation of samples with the antibody mix for extracellular staining, prepare all required buffers to detect intracellular cytokine production in T cells, as described in the datasheet of the BD Cytofix/Cytoperm Fixation/Permeabilization Solution Kit (https://www.bdbiosciences.com/ds/pm/others/554714_554715_555028_Book_Website.pdf). Discard the supernatant and resuspend samples and eBeads with 100 μL fixation buffer. Incubate samples on ice for 30 min in the dark. Prepare the intracellular cytokine antibody staining as described in step 12o and store in the fridge at 4°C (see Table 8). Centrifuge plate at 400 × g for 4 min at 4°C. Discard the supernatant and resuspend non- and PMA/ionomycin-stimulated splenocytes with 100 μL of intracellular staining antibody mix. Resuspend unstained and single-stained cell controls with 100 μL 1× Permeabilization buffer and add x μL of the relevant intracellular staining antibody to the proper sample. In this case x μL is calculated based on the antibody's final dilution, as indicated in Table 8. Resuspend eBeads with 200 μL 1× Permeabilization buffer and add 0.5 μL of the corresponding intracellular antibody to the beads, except for Alexa Fluor 700 and APC-eFluor780: 1 μL and for PE, PE-tandem, and BV dyes: 0.2 μL. Incubate samples on ice for 30 min in the dark. Add 100 μL 1× Permeabilization buffer to each sample (not to the eBeads) and centrifuge at 400 × g for 4 min at 4°C. Discard the supernatant and resuspend samples and eBeads with 200 μL FACS buffer (see Materials and equipment). Transfer samples in pre-labeled 1.2 mL FACS tubes and store samples in the fridge at 4°C until detection. Pause point: Since the cells are fixed, one can collect the data the following day. Antibody mix for the extracellular staining of splenic T cells Antibody mix for the intracellular staining of splenic T cells Antibody mix for the extracellular staining of thymic T cells Antibody mix for the intracellular staining of thymic T cells Antibody mix for the extracellular staining of T cells in the blood of mice Antibody mix for the intracellular staining of T cells in the blood of mice Antibody mix for the extracellular staining of PMA/ionomycin-stimulated splenic T cells Antibody mix for the intracellular staining of PMA/ionomycin-stimulated splenic T cells Layout of a 96-well v-bottom plate setup for the staining of splenic T cell activation and Treg cell functionality of ten mice Splenocytes are stained with the antibody mix for the extracellular staining and the intracellular staining as indicated in Tables 1 and 2 and described in step 12, single-stained cell controls and eBeads compensation controls are stained with the indicated fluorophore-conjugated anti-mouse antibodies, based on Tables 1 and 2. FMO, fluorescence minus one; FVD, fixable viability dye.

Data collection

Timing: 3–4 h This step details how to collect flow data using a five laser BD LSRFortessa cytometer and analyze them using the FlowJo software. The staining of T cells and Tregs in thymus and blood (Tables 3, 4, 5, and 6) can also be acquired using a three laser BD LSR II cytometer or a three or four laser BD Fortessa cytometer. Acquire data with a BD LSRFortessa 5 laser flow cytometer within 24 h after staining at a flow rate of 8000 events/s or less. Use unstained and single-stained cell controls to set suitable PMT voltages. For the FSC and SSC, voltages are set so that the cells can be discriminated from the debris, which should be present in the lower left of a FSC-A versus SSC-A plot (see Figures 2, 3, 4, and 5). For the other parameters the CS&T baseline target voltages are a good starting point to set PMT voltages. If a positive population of a single-stained cell control is not on scale, lower the PMT voltage to have the positive population on scale. For auto-compensation, use the eBeads control samples and the heat-killed cell sample stained with Fixable Viability Dye eFluor 506. Once the PMT voltages are set and the auto-compensation is done, acquire at least 0.5 million living cells per tube.
Figure 2

Gating strategy for T cell activation in spleen

CD4+ and CD8+ naive (CD44−CD62L+), TEM (CD44+CD62L−) and TCM (CD44+CD62L+) cells, CTLA4+CD4+ T cells, total Treg cells (FoxP3+) and CD25+FoxP3+ Treg cells, Treg functionality markers (TNFR2+ or CTLA4+), cTregs (CD44loCD62Lhi), and eTregs (CD44hiCD62Llo).

Figure 3

Gating strategy for CD4−CD8− (DN), CD4+CD8+ (DP), CD4+CD8− (SP), CD4−CD8+ (SP) thymocytes, and FoxP3+CD4+CD8− thymic Tregs

Figure 4

Gating strategy for T cell activation and Treg cells in blood

CD4+ and CD8+ naive (CD44−CD62L+), TEM (CD44+CD62L−) and TCM (CD44+CD62L+) cells and Treg cells (FoxP3+CD4+). Smooth pseudocolor plots are used to facilitate the gating.

Figure 5

Gating strategy for cytokine production by T cells

Activated CD4+ and CD8+ T cells are indicated by their CD44 expression. CD4+ T cells expressing IL-2, IL-4, IL-17, IFN-γ, and TNF. CD8+ T cells expressing IL-2, IFN-γ, and TNF.

Gating strategy for T cell activation in spleen CD4+ and CD8+ naive (CD44−CD62L+), TEM (CD44+CD62L−) and TCM (CD44+CD62L+) cells, CTLA4+CD4+ T cells, total Treg cells (FoxP3+) and CD25+FoxP3+ Treg cells, Treg functionality markers (TNFR2+ or CTLA4+), cTregs (CD44loCD62Lhi), and eTregs (CD44hiCD62Llo). Gating strategy for CD4−CD8− (DN), CD4+CD8+ (DP), CD4+CD8− (SP), CD4−CD8+ (SP) thymocytes, and FoxP3+CD4+CD8− thymic Tregs Gating strategy for T cell activation and Treg cells in blood CD4+ and CD8+ naive (CD44−CD62L+), TEM (CD44+CD62L−) and TCM (CD44+CD62L+) cells and Treg cells (FoxP3+CD4+). Smooth pseudocolor plots are used to facilitate the gating. Gating strategy for cytokine production by T cells Activated CD4+ and CD8+ T cells are indicated by their CD44 expression. CD4+ T cells expressing IL-2, IL-4, IL-17, IFN-γ, and TNF. CD8+ T cells expressing IL-2, IFN-γ, and TNF. If the researcher is not familiar with setting up PMT voltages and performing auto- compensation, we advise to get assistance from a more experienced researcher. The acquired data can be analyzed with FlowJo software using linear scales for FSC-A, SSC-A and FCS-H, and biexponential scales for the other markers.

Expected outcomes

This protocol describes gating strategies to study T cells in mouse thymus, spleen, and blood. We defined the different T cell populations based on extracellular and intracellular markers. For all panels we first create a cell gate based on SSC-A and FSC-A parameters. We continue by gating single cells by using the FSC-H and FSC-A parameters. Next, we use eFluor 506 Fixable Viability Dye to separate dead from alive cells (Figures 2, 3, 4, and 5). To distinguish CD4−CD8− (DN), CD4+CD8+ (DP) and CD4+CD8− or CD4−CD8+ (SP) thymocytes, we look at CD4 and CD8a expression on living cells (Figure 3). We did not include a CD3e antibody, since not all DN thymocytes express CD3e on their surface and gating for CD3e prior to CD4 and CD8a gating would result in loss of some DN thymocytes. On the living cell population, we can also gate for T cells by using an anti-CD3e antibody (Figures 2 and 4) or T and B cells by using anti-CD3e and anti-CD45R/B220 antibodies (Figure 5). T cells are further divided in CD4+ and CD8+ T cell populations based on the expression of CD4 and CD8a, respectively (Figures 2, 4, and 5). To define the activation status of splenic and circulating CD4+ T and CD8+ T cells, we use anti-CD44 and anti-CD62L antibodies, resulting in plots with CD44−CD62L+ naive, CD44+CD62L− effector memory (TEM) and CD44+CD62L+ central memory (TCM) cells (Figures 2 and 4). Thymic and circulating Treg cells are defined as FoxP3+CD4+ T cells (Figures 3 and 4), while splenic Treg cells are also more specifically defined as FoxP3+CD25+CD4+ T cells (Figure 2). The splenic FoxP3+ Treg cells are then further divided in CD44loCD62Lhi naive central Treg cells (cTregs) and CD44hiCD62Llo effector Treg cells (eTregs) (Di Pilato et al., 2019; Yang et al., 2019). Finally, with the help of FMO controls and the CTLA4 expression on CD4+ T cells, we can gate for the expression of TNFR2 (CD120b) and CTLA4 (CD152), which are functionality markers for FoxP3+CD4+ Treg cells (Figure 2) (Chen et al., 2008; Klocke et al, 2017). In addition, we developed a gating strategy to study T helper and cytotoxic T cell populations in mouse spleen, based on the intracellular expression of cytokines (Figure 5). PMA/ionomycin/BFA-stimulated cells will produce cytokines, but these cytokines cannot be secreted since BFA is used. By using the BFA only negative control, we can determine PMA/ionomycin-induced IFN-γ (Th1), IL-4 (Th2), IL-17 (Th17), IL-2 and TNF producing CD4+ T cells. Similarly, we determined cytotoxic CD8+ T cells that are subdivided into three categories based on IL-2, IFN-γ and TNF production. We have also included the CD44 marker to be able to distinguish activated CD44hiCD4+ and CD44hiCD8+ T cells. These CD44hi cells can be submitted to a similar gating strategy for cytokine expression (Figure 6).
Figure 6

Gating strategy for cytokine production by activated T cells

Activated CD44hiCD4+ and CD44hiCD8+ T cells expressing IL-2, IL-4, IL-17, IFN-γ, and TNF.

Stimulation of T cells with PMA/ionomycin (for 4 h) can cause some downregulation of surface CD3 and CD4 expression, which can complicate the gating of CD3+ and CD4+ T cells. However, this problem can be solved by using the negative control (only BFA-treated splenocytes) to set the required gates. Gating strategy for cytokine production by activated T cells Activated CD44hiCD4+ and CD44hiCD8+ T cells expressing IL-2, IL-4, IL-17, IFN-γ, and TNF.

Limitations

This protocol provides the basics to study thymic, splenic, and circulating T cells in mice. The protocol can also be used to analyze T cell activation, Treg functionality, and cytokine production of T cells from lymph nodes. To obtain single-cell suspensions of these lymph nodes, one can use the isolation protocol for thymus, but for the last step one has to adjust the volume of T cell culture medium according to the number of lymph nodes. However, the protocol has not been optimized for the analysis of T cells in non-lymphoid tissues, which requires a more labor-intensive method to isolate immune cells, such as enzymatic digestion of the tissue and density gradient centrifugation. Though this is a very comprehensive protocol concerning T cells, it does not provide any data concerning the early stages of thymocyte development. Early stages of thymocyte development are well defined by the surface expression of CD44 and CD25 on CD4−CD8− T cells. Therefore, the inclusion of Alexa Fluor 700-conjugated anti-CD44 and BUV395-conjugated anti-CD25 antibodies in the thymocyte flow panel (see Table 2) would solve this issue. In addition, the presence of CD25 in this panel would allow for the separation of mature CD25+FoxP3+ Tregs from CD25+ Treg and FoxP3lo Treg progenitors in the thymus (Owen et al., 2019). Furthermore, the protocol does not provide any information regarding follicular T helper cells and γδ-T cells in mouse spleen. For a more comprehensive analysis of circulating and peripheral immune cells using flow cytometry, we recommend referring to "Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)" (Cossarizza et al., 2019).

Troubleshooting

Problem 1

Contamination of blood single-cell suspensions with red blood cells after ACK lysis step.

Potential solution

The potential reason for this problem might be that the ACK lysis buffer was not effective enough. A second ACK lysis step can be included in which the pellet is dissolved in 3 mL of ACK lysis buffer for 3 min and the other steps of the protocol are repeated. However, fixation of samples with fixation buffers provided with the intracellular staining sets should overcome this problem.

Problem 2

Small numbers of PMA/Ionomycin/BFA-stimulated cells after transfer of cells from the 48-well flat-bottom culture plate to the 96-well polypropylene v-bottom plate. The potential reason for this problem is the sticking of stimulated cells to the bottom of the 48-well flat-bottom culture plate. Therefore, take the time to loosen all cells by pipetting up and down in a clockwise fashion. After cell transfer, one can inspect the plate to see if cells still remain in the culture plate. If this is the case, add 200 μl 1× D-PBS to the wells and start detaching the cells in the same fashion as before. These cells can then be added to the pellet obtained after the first centrifugation step and then the subsequent steps of the protocol can be followed.

Problem 3

No positive staining of some extracellular markers by flow cytometry. Several reasons may result in this problem. 1) antibody was not added. Ensure adding all the antibodies to the antibody mixes the next time you repeat the experiment; 2) use of a different antibody clone. Using a different antibody clone than the one indicated in our protocol may lead to incompatibility with the fixation step. Therefore, we recommend using the antibody clones mentioned in our protocol. However, if you want to use another clone, please check clone's compatibility with fixation buffer in one of the following links: https://www.thermofisher.com/be/en/home/life-science/cell-analysis/cell-analysis-learning-center/cell-analysis-resource-library/ebioscience-resources/antibody-fixation-considerations.html and https://www.biolegend.com/en-us/fixation; 3) inappropriate PMT voltages. The use of unstained and single-stained cell controls will help to detect the appropriate PMT voltages and overcome this problem; 4) do a titration of the antibody.

Problem 4

Weak or undetectable intracellular staining of cytokines in PMA/ionomycin/BFA-treated cells. There are several possible reasons for this problem. 1) not adding BFA in the PMA/ionomycin mix. Ensure that you add BFA in the stimulation mix and perform a new experiment; 2) lower efficiency of BFA due to repeated freeze/thaw of BFA, which can affect its inhibitory efficiency. Avoid using BFA aliquots that have been subjected to freeze/thaw for more than three times; 3) insufficient production of cytokines by PMA/ionomycin/BFA-stimulated cells. To overcome this problem, culture the PMA/ionomycin/BFA-stimulated cells for 6 h instead of 4 h. Be aware that culturing cells with BFA for more than 24 h can negatively influence the cell viability; 4) insufficient binding of fluorophore-conjugated anti-cytokine antibodies with their targets, due to the accidental use of the 1× Permeabilization buffer of the FoxP3/Transcription Factor Staining Buffer. Ensure that the fixation, the permeabilization and the intracellular cytokine staining of cells are performed using reagents of the BD Cytofix/Cytoperm Fixation/Permeabilization Kit.

Problem 5

Undetectable intracellular FoxP3 expression in CD4+ T cells. The following reason might cause this problem. Insufficient binding of the anti-FoxP3 antibody to its nuclear target due to the accidental use of the BD Cytofix/Cytoperm Fixation/Permeabilization Kit instead of the FoxP3/Transcription Factor Staining Buffer Set during the intracellular staining procedure. In this case, the nucleus will remain intact and the anti-FoxP3 antibody will not bind to FoxP3. To solve this problem, ensure that you always use the fixation and permeabilization buffers of the FoxP3/Transcription Factor Staining Buffer Set during the intracellular FoxP3 detection.

Resource availability

Lead contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Rudi Beyaert (rudi.beyaert@irc.vib-ugent.be).

Materials availability

This study did not generate new unique reagents.

Data and code availability

This study did not generate or analyze any datasets.
REAGENT or RESOURCESOURCEIDENTIFIER
Antibodies

Anti-mouse CD3e PE-Cy5 (145-2C11)TONBO BiosciencesCat# 55-0031; RRID: AB_2621815
Anti-mouse CD4 APC-eFluor 780 (RM4-5)eBioscienceCat# 47-0042-82; RRID: AB_1272183
Anti-mouse CD4 BUV395 (GK1.5)BDCat# 563790; RRID: AB_2738426
Anti-mouse CD8a PE-Cy7 (53-6.7)eBioscienceCat# 25-0081-82; RRID: AB_469584
Anti-mouse CD8a FITC (53-6.7)BDCat# 553030; RRID: AB_394568
Anti-mouse CD16/32 purified (Mouse BD FC Block)BDCat# 553142; RRID: AB_394657
Anti-mouse CD25 BUV395 (PC61)BDCat# 564022; RRID: AB_2722574
Anti-mouse CD44 Alexa Fluor 700eBioscienceCat# 12-0441-81; RRID: AB_465663
Anti-mouse CD44 PE (IM7)BioLegendCat# 103012; RRID: AB_312963
Anti-mouse CD45R/B220 BUV496 (RA3-6B2)BDCat# 612950; RRID: AB_2722578
Anti-mouse CD62L PE (MEL-14)eBioscienceCat# 12-0621-82: RRID: AB_465721
Anti-mouse CD62L eFluor 450 (MEL-14)eBioscienceCat# 48-0621-80; RRID: AB_1963591
Anti-mouse CD120b BV421 (TR75-89)BDCat# 564088; RRID: AB_2738585
Anti-mouse CD152 PE-eFluor 610 (UC10-4B9)eBioscienceCat# 61-1522-82; RRID: AB_2574580
Anti-mouse FoxP3 APC (FJK-16s)eBioscienceCat# 17-5773-82; RRID: AB_469456
Anti-mouse IFN gamma PE-Cy7 (XMG1.2)eBioscienceCat# 25-7311-82; RRID: AB_469680
Anti-mouse IL-2 APC-Cy7 (JES6-5H4)BDCat# 560547; RRID: AB_1727544
Anti-mouse IL-4 APC (11B11)eBioscienceCat# 17-7041-81; RRID: AB_469493
Anti-mouse IL-17 PerCP-Cyanine5.5 (eBio17B7)eBioscienceCat# 45-7177-80; RRID: AB_925754
Anti-mouse TNF Alexa Fluor 700 (MP6-XT22)BDCat# 558000; RRID: AB_396980

Chemicals, peptides, and recombinant proteins

2-Mercaptoethanol (50 mM)GibcoCat# 31350010
ACK lysis bufferGibcoCat# A1049201
Brefeldin ASigma-AldrichCat# B7651
1× D-PBS liquid w/o Ca and MgGibcoCat# 14190-094
Dimethyl sulfoxide Hybri-Max (DMSO)Sigma-AldrichCat# D2650
EDTA disodium salt dihydrate 99.0-101.0%, AnalaR NORMAPUR ACS, Reag. Ph. Eur. analytical reagentVWRCat# 20302.293
Ethanol absolute, EMSURE ACS, ISO, Reag. Ph. Eur. for analysis, SupelcoVWRCat# 1.00983.1011
Fetal bovine serumBodincon/a
Ionomycin calcium salt (from Streptomyces conglobatus)Sigma-AldrichCat# 407952
L-Glutamine (200mM)LonzaCat# BE17-605F
Penicillin-streptomycin solution stabilizedSigma-AldrichCat# P4333
Phorbol 12-myristate 13-acetate (PMA)Sigma-AldrichCat# P8139
RPMI 1640 w/o NaHCO3, w/ L-glutamineGibcoCat# 52400-025
Sodium pyruvate solution (100 mM)Sigma-AldrichCat# S8636
Trypan blueSigma-AldrichCat# 1.11732

Critical commercial assays

BD Horizon Brilliant Stain BufferBDCat# 566349
Fixable Viability Dye eFluor 506eBioscienceCat# 65-0866-14
Fixation/Permeabilization Solution KitBDCat# 554714
FoxP3/Transcription Factor Staining Buffer SeteBioscienceCat# 00-5523-00
UltraComp eBeads Compensation BeadsInvitrogenCat# 01-2222-42

Experimental models: organisms/strains

Mouse: C57BL/6SPF-IRC animal house facility LA2400526n/a

Software and algorithms

BD FACSDiva Software v8.0BDhttps://www.bdbiosciences.com/cn/instruments/research/software/flow-cytometry-acquisition/bd-facsdiva-software/m/111112/resourcestools
FlowJo v10.7.0Treestarhttps://www.flowjo.com

Other

15 mL centrifuge tubesCorningCat# 430791
50 mL centrifuge tubesCorningCat# CLS430897
96-well polypropylene storage microplatesNuncCat# 249944
BD LSRFortessa 5 laser flow cytometerBDn/a
Cell culture CO2 incubatorThermo ScientificCat# 3311
Cell strainers 70 μm whiteFalconCat# 352350
CentrifugeThermo ScientificMultifuge 3SR+
Clustertubes 1.2 mL for FACSCostarCat# COS4401
Curved forceps (Dumont #7b Medical Forceps-Inox Standard Tip)Fine science toolsCat# 11270-20
Gosselin Petri Dish 100 × 15 mm, 3 Vents, AsepticCorningCat# SB93-101
Injection needles, 26G × 1/2 inchHSW FINE-JECTn/a
Cell counting chamber without clamps, dark lined, BürkerMARIENFELDCat# 0640210
SafeSeal tube 1.5 mLSARSTEDT AG & Co. KGCat# 72.706
Stericup Quick Release-GP sterile vacuum filtration systemMilliporeCat# S2GPU05RE
Straight forceps with blunt points L120 mmSurpodoCat# A11623
Student Fine scissors straight 11.5 cmFine Science ToolsCat# 91460-11
Syringe 2 mL (3 mL) luerNorm-JectCat# 4020-000V0
Tissue culture plate, 48 well, flat bottom with low evaporation lidFalconCat# 353078
  8 in total

1.  CTLA-4 expressed by FOXP3+ regulatory T cells prevents inflammatory tissue attack and not T-cell priming in arthritis.

Authors:  Katrin Klocke; Rikard Holmdahl; Kajsa Wing
Journal:  Immunology       Date:  2017-06-20       Impact factor: 7.397

2.  Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4+CD25+FoxP3+ T regulatory cells: applicability to tumor-infiltrating T regulatory cells.

Authors:  Xin Chen; Jeffrey J Subleski; Heather Kopf; O M Zack Howard; Daniela N Männel; Joost J Oppenheim
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

3.  Bcl10 is required for the development and suppressive function of Foxp3+ regulatory T cells.

Authors:  Dandan Yang; Xueqiang Zhao; Xin Lin
Journal:  Cell Mol Immunol       Date:  2019-10-08       Impact factor: 11.530

4.  Does age matter? The impact of rodent age on study outcomes.

Authors:  Samuel J Jackson; Nick Andrews; Doug Ball; Ilaria Bellantuono; James Gray; Lamia Hachoumi; Alan Holmes; Judy Latcham; Anja Petrie; Paul Potter; Andrew Rice; Alison Ritchie; Michelle Stewart; Carol Strepka; Mark Yeoman; Kathryn Chapman
Journal:  Lab Anim       Date:  2016-07-10       Impact factor: 2.471

5.  Targeting the CBM complex causes Treg cells to prime tumours for immune checkpoint therapy.

Authors:  Mauro Di Pilato; Edward Y Kim; Bruno L Cadilha; Jasper N Prüßmann; Mazen N Nasrallah; Davide Seruggia; Shariq M Usmani; Sandra Misale; Valentina Zappulli; Esteban Carrizosa; Vinidhra Mani; Matteo Ligorio; Ross D Warner; Benjamin D Medoff; Francesco Marangoni; Alexandra-Chloe Villani; Thorsten R Mempel
Journal:  Nature       Date:  2019-05-15       Impact factor: 49.962

6.  Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition).

Authors:  Andrea Cossarizza; Hyun-Dong Chang; Andreas Radbruch; Andreas Acs; Dieter Adam; Sabine Adam-Klages; William W Agace; Nima Aghaeepour; Mübeccel Akdis; Matthieu Allez; Larissa Nogueira Almeida; Giorgia Alvisi; Graham Anderson; Immanuel Andrä; Francesco Annunziato; Achille Anselmo; Petra Bacher; Cosima T Baldari; Sudipto Bari; Vincenzo Barnaba; Joana Barros-Martins; Luca Battistini; Wolfgang Bauer; Sabine Baumgart; Nicole Baumgarth; Dirk Baumjohann; Bianka Baying; Mary Bebawy; Burkhard Becher; Wolfgang Beisker; Vladimir Benes; Rudi Beyaert; Alfonso Blanco; Dominic A Boardman; Christian Bogdan; Jessica G Borger; Giovanna Borsellino; Philip E Boulais; Jolene A Bradford; Dirk Brenner; Ryan R Brinkman; Anna E S Brooks; Dirk H Busch; Martin Büscher; Timothy P Bushnell; Federica Calzetti; Garth Cameron; Ilenia Cammarata; Xuetao Cao; Susanna L Cardell; Stefano Casola; Marco A Cassatella; Andrea Cavani; Antonio Celada; Lucienne Chatenoud; Pratip K Chattopadhyay; Sue Chow; Eleni Christakou; Luka Čičin-Šain; Mario Clerici; Federico S Colombo; Laura Cook; Anne Cooke; Andrea M Cooper; Alexandra J Corbett; Antonio Cosma; Lorenzo Cosmi; Pierre G Coulie; Ana Cumano; Ljiljana Cvetkovic; Van Duc Dang; Chantip Dang-Heine; Martin S Davey; Derek Davies; Sara De Biasi; Genny Del Zotto; Gelo Victoriano Dela Cruz; Michael Delacher; Silvia Della Bella; Paolo Dellabona; Günnur Deniz; Mark Dessing; James P Di Santo; Andreas Diefenbach; Francesco Dieli; Andreas Dolf; Thomas Dörner; Regine J Dress; Diana Dudziak; Michael Dustin; Charles-Antoine Dutertre; Friederike Ebner; Sidonia B G Eckle; Matthias Edinger; Pascale Eede; Götz R A Ehrhardt; Marcus Eich; Pablo Engel; Britta Engelhardt; Anna Erdei; Charlotte Esser; Bart Everts; Maximilien Evrard; Christine S Falk; Todd A Fehniger; Mar Felipo-Benavent; Helen Ferry; Markus Feuerer; Andrew Filby; Kata Filkor; Simon Fillatreau; Marie Follo; Irmgard Förster; John Foster; Gemma A Foulds; Britta Frehse; Paul S Frenette; Stefan Frischbutter; Wolfgang Fritzsche; David W Galbraith; Anastasia Gangaev; Natalio Garbi; Brice Gaudilliere; Ricardo T Gazzinelli; Jens Geginat; Wilhelm Gerner; Nicholas A Gherardin; Kamran Ghoreschi; Lara Gibellini; Florent Ginhoux; Keisuke Goda; Dale I Godfrey; Christoph Goettlinger; Jose M González-Navajas; Carl S Goodyear; Andrea Gori; Jane L Grogan; Daryl Grummitt; Andreas Grützkau; Claudia Haftmann; Jonas Hahn; Hamida Hammad; Günter Hämmerling; Leo Hansmann; Goran Hansson; Christopher M Harpur; Susanne Hartmann; Andrea Hauser; Anja E Hauser; David L Haviland; David Hedley; Daniela C Hernández; Guadalupe Herrera; Martin Herrmann; Christoph Hess; Thomas Höfer; Petra Hoffmann; Kristin Hogquist; Tristan Holland; Thomas Höllt; Rikard Holmdahl; Pleun Hombrink; Jessica P Houston; Bimba F Hoyer; Bo Huang; Fang-Ping Huang; Johanna E Huber; Jochen Huehn; Michael Hundemer; Christopher A Hunter; William Y K Hwang; Anna Iannone; Florian Ingelfinger; Sabine M Ivison; Hans-Martin Jäck; Peter K Jani; Beatriz Jávega; Stipan Jonjic; Toralf Kaiser; Tomas Kalina; Thomas Kamradt; Stefan H E Kaufmann; Baerbel Keller; Steven L C Ketelaars; Ahad Khalilnezhad; Srijit Khan; Jan Kisielow; Paul Klenerman; Jasmin Knopf; Hui-Fern Koay; Katja Kobow; Jay K Kolls; Wan Ting Kong; Manfred Kopf; Thomas Korn; Katharina Kriegsmann; Hendy Kristyanto; Thomas Kroneis; Andreas Krueger; Jenny Kühne; Christian Kukat; Désirée Kunkel; Heike Kunze-Schumacher; Tomohiro Kurosaki; Christian Kurts; Pia Kvistborg; Immanuel Kwok; Jonathan Landry; Olivier Lantz; Paola Lanuti; Francesca LaRosa; Agnès Lehuen; Salomé LeibundGut-Landmann; Michael D Leipold; Leslie Y T Leung; Megan K Levings; Andreia C Lino; Francesco Liotta; Virginia Litwin; Yanling Liu; Hans-Gustaf Ljunggren; Michael Lohoff; Giovanna Lombardi; Lilly Lopez; Miguel López-Botet; Amy E Lovett-Racke; Erik Lubberts; Herve Luche; Burkhard Ludewig; Enrico Lugli; Sebastian Lunemann; Holden T Maecker; Laura Maggi; Orla Maguire; Florian Mair; Kerstin H Mair; Alberto Mantovani; Rudolf A Manz; Aaron J Marshall; Alicia Martínez-Romero; Glòria Martrus; Ivana Marventano; Wlodzimierz Maslinski; Giuseppe Matarese; Anna Vittoria Mattioli; Christian Maueröder; Alessio Mazzoni; James McCluskey; Mairi McGrath; Helen M McGuire; Iain B McInnes; Henrik E Mei; Fritz Melchers; Susanne Melzer; Dirk Mielenz; Stephen D Miller; Kingston H G Mills; Hans Minderman; Jenny Mjösberg; Jonni Moore; Barry Moran; Lorenzo Moretta; Tim R Mosmann; Susann Müller; Gabriele Multhoff; Luis Enrique Muñoz; Christian Münz; Toshinori Nakayama; Milena Nasi; Katrin Neumann; Lai Guan Ng; Antonia Niedobitek; Sussan Nourshargh; Gabriel Núñez; José-Enrique O'Connor; Aaron Ochel; Anna Oja; Diana Ordonez; Alberto Orfao; Eva Orlowski-Oliver; Wenjun Ouyang; Annette Oxenius; Raghavendra Palankar; Isabel Panse; Kovit Pattanapanyasat; Malte Paulsen; Dinko Pavlinic; Livius Penter; Pärt Peterson; Christian Peth; Jordi Petriz; Federica Piancone; Winfried F Pickl; Silvia Piconese; Marcello Pinti; A Graham Pockley; Malgorzata Justyna Podolska; Zhiyong Poon; Katharina Pracht; Immo Prinz; Carlo E M Pucillo; Sally A Quataert; Linda Quatrini; Kylie M Quinn; Helena Radbruch; Tim R D J Radstake; Susann Rahmig; Hans-Peter Rahn; Bartek Rajwa; Gevitha Ravichandran; Yotam Raz; Jonathan A Rebhahn; Diether Recktenwald; Dorothea Reimer; Caetano Reis e Sousa; Ester B M Remmerswaal; Lisa Richter; Laura G Rico; Andy Riddell; Aja M Rieger; J Paul Robinson; Chiara Romagnani; Anna Rubartelli; Jürgen Ruland; Armin Saalmüller; Yvan Saeys; Takashi Saito; Shimon Sakaguchi; Francisco Sala-de-Oyanguren; Yvonne Samstag; Sharon Sanderson; Inga Sandrock; Angela Santoni; Ramon Bellmàs Sanz; Marina Saresella; Catherine Sautes-Fridman; Birgit Sawitzki; Linda Schadt; Alexander Scheffold; Hans U Scherer; Matthias Schiemann; Frank A Schildberg; Esther Schimisky; Andreas Schlitzer; Josephine Schlosser; Stephan Schmid; Steffen Schmitt; Kilian Schober; Daniel Schraivogel; Wolfgang Schuh; Thomas Schüler; Reiner Schulte; Axel Ronald Schulz; Sebastian R Schulz; Cristiano Scottá; Daniel Scott-Algara; David P Sester; T Vincent Shankey; Bruno Silva-Santos; Anna Katharina Simon; Katarzyna M Sitnik; Silvano Sozzani; Daniel E Speiser; Josef Spidlen; Anders Stahlberg; Alan M Stall; Natalie Stanley; Regina Stark; Christina Stehle; Tobit Steinmetz; Hannes Stockinger; Yousuke Takahama; Kiyoshi Takeda; Leonard Tan; Attila Tárnok; Gisa Tiegs; Gergely Toldi; Julia Tornack; Elisabetta Traggiai; Mohamed Trebak; Timothy I M Tree; Joe Trotter; John Trowsdale; Maria Tsoumakidou; Henning Ulrich; Sophia Urbanczyk; Willem van de Veen; Maries van den Broek; Edwin van der Pol; Sofie Van Gassen; Gert Van Isterdael; René A W van Lier; Marc Veldhoen; Salvador Vento-Asturias; Paulo Vieira; David Voehringer; Hans-Dieter Volk; Anouk von Borstel; Konrad von Volkmann; Ari Waisman; Rachael V Walker; Paul K Wallace; Sa A Wang; Xin M Wang; Michael D Ward; Kirsten A Ward-Hartstonge; Klaus Warnatz; Gary Warnes; Sarah Warth; Claudia Waskow; James V Watson; Carsten Watzl; Leonie Wegener; Thomas Weisenburger; Annika Wiedemann; Jürgen Wienands; Anneke Wilharm; Robert John Wilkinson; Gerald Willimsky; James B Wing; Rieke Winkelmann; Thomas H Winkler; Oliver F Wirz; Alicia Wong; Peter Wurst; Jennie H M Yang; Juhao Yang; Maria Yazdanbakhsh; Liping Yu; Alice Yue; Hanlin Zhang; Yi Zhao; Susanne Maria Ziegler; Christina Zielinski; Jakob Zimmermann; Arturo Zychlinsky
Journal:  Eur J Immunol       Date:  2019-10       Impact factor: 6.688

7.  Thymic regulatory T cells arise via two distinct developmental programs.

Authors:  David L Owen; Shawn A Mahmud; Louisa E Sjaastad; Jason B Williams; Justin A Spanier; Dimitre R Simeonov; Roland Ruscher; Weishan Huang; Irina Proekt; Corey N Miller; Can Hekim; Jonathan C Jeschke; Praful Aggarwal; Ulrich Broeckel; Rebecca S LaRue; Christine M Henzler; Maria-Luisa Alegre; Mark S Anderson; Avery August; Alexander Marson; Ye Zheng; Calvin B Williams; Michael A Farrar
Journal:  Nat Immunol       Date:  2019-01-14       Impact factor: 25.606

  8 in total
  2 in total

Review 1.  Novel Techniques and Future Perspective for Investigating Critical-Size Bone Defects.

Authors:  Elijah Ejun Huang; Ning Zhang; Huaishuang Shen; Xueping Li; Masahiro Maruyama; Takeshi Utsunomiya; Qi Gao; Roberto A Guzman; Stuart B Goodman
Journal:  Bioengineering (Basel)       Date:  2022-04-11

2.  Heterologous saRNA Prime, DNA Dual-Antigen Boost SARS-CoV-2 Vaccination Elicits Robust Cellular Immunogenicity and Cross-Variant Neutralizing Antibodies.

Authors:  Adrian Rice; Mohit Verma; Emily Voigt; Peter Battisti; Sam Beaver; Sierra Reed; Kyle Dinkins; Shivani Mody; Lise Zakin; Shiho Tanaka; Brett Morimoto; C Anders Olson; Elizabeth Gabitzsch; Jeffrey T Safrit; Patricia Spilman; Corey Casper; Patrick Soon-Shiong
Journal:  Front Immunol       Date:  2022-07-15       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.